← Back to Search

Topical Corticosteroid and Retinoid Combination

Duobrii for Scalp Psoriasis

Phase 4

Waitlist Available

Led By Zoe D Draelos, MD

Research Sponsored by Dermatology Consulting Services, PLLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

1. Males or non-pregnant females 18+ years of age. 2. Plaque type moderate to severe scalp psoriasis suitable for topical treatment.

3. Subjects must be in general good health as determined from a medical history.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 weeks

Awards & highlights

Study Summary

This trial tests a lotion to improve hair growth, reduce scalp itch, and improve scalp psoriasis in 12 weeks. Patients' perceptions of the lotion's value are also assessed.

Eligible Conditions

Scalp Psoriasis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Hair Growth

Scalp Itch

Trial Design

1Treatment groups

Experimental Treatment

Group I: Active ArmExperimental Treatment1 Intervention

0.045% Tazarotene/0.01% Habetasol Lotion apply once daily at bedtime to the scalp afflicted with psoriasis

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

0.045% Tazarotene/0.01% Halobetasol Lotion

2023

Completed Phase 4

~20

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Ortho DermatologicsIndustry Sponsor

4 Previous Clinical Trials

1,201 Total Patients Enrolled

Dermatology Consulting Services, PLLCLead Sponsor

2 Previous Clinical Trials

50 Total Patients Enrolled

Zoe D Draelos, MDPrincipal InvestigatorDermatology Consulting Services, PLLC

5 Previous Clinical Trials

279 Total Patients Enrolled

Media Library

0.045% Tazarotene/0.01% Halobetasol Lotion (Topical Corticosteroid and Retinoid Combination) Clinical Trial Eligibility Overview. Trial Name: NCT05872256 — Phase 4

Scalp Psoriasis Research Study Groups: Active Arm

Scalp Psoriasis Clinical Trial 2023: 0.045% Tazarotene/0.01% Halobetasol Lotion Highlights & Side Effects. Trial Name: NCT05872256 — Phase 4

0.045% Tazarotene/0.01% Halobetasol Lotion (Topical Corticosteroid and Retinoid Combination) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05872256 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants is the maximum capacity for this clinical research?

"Affirmative, the information posted on clinicaltrials.gov confirms that this medical experiment is presently recruiting individuals. The study was originally published on June 1st 2023 and has since been updated for a final time on May 14th 2023; it seeks to enroll twenty patients from one trial site."

Answered by AI

Has this intervention been validated by the FDA?

"Due to the fact that this medication has been approved as part of a Phase 4 clinical trial, it can be assumed with some confidence that its safety level is at least 3."

Answered by AI

Are there any opportunities available for enrollment in this scientific research?

"The clinical trial, which was initially created on June 1st 2023 and modified for the last time on May 14th 2023, is currently open to participants according to clinicaltrials.gov's data."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis

2023. "A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05872256.